Research
Dr. Paul Naser from the Department of Neurosurgery at Heidelberg University Hospital and the Heidelberg Faculty of Medicine at Heidelberg University has been awarded the German Society for Neurointensive and Emergency Medicine (DGNI) Young Investigator Award. The prize is endowed with 20,000 euros in funding. He receives the prize for a research project that aims […]
read more
EU-OPENSCREEN announces new service category: Chemoproteomics and Spatial MS-Based Omics
Three institutions have joined our consortium as official Chemoproteomics and Spatial Mass Spectrometry (MS)-Based Omics partner sites, enhancing the services we can offer to the research community in the areas of target identification and validation. Phil Gribbon, Director General of EU-OPENSCREEN, emphasised: “The three new chemoproteomics sites joining the EU-OPENSCREEN partner network provide a significant boost […]
read more
Low-cost cancer prevention: AI-generated influencers reach at-risk groups on social media
Artificial Intelligence (AI) is transforming cancer prevention: A groundbreaking study conducted at the German Cancer Research Center (DKFZ) demonstrates that AI-generated social media influencers can effectively reach at-risk groups with preventive health messages—at a fraction of the cost of traditional campaigns. In this pilot study, researchers created a virtual influencer named “Wanda” who shared educational […]
read more
YUMAB and InSCREENeX are developing an innovative “Mammalian Display” screening platform to accelerate antibody development.
Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project “Mammalian Display,” the two Braunschweig-based companies are developing a platform that enables the screening of antibody libraries […]
read more
New Member: Welcome in our cluster to Menarini Biotech
Menarini Biotech (MBH) is a leading CDMO specializing in Process Development and GMP manufacturing across various therapeutic areas. With a mission to be a reliable, agile, and innovative partner, MBH empowers its customers to bring life-saving biotherapeutics to patients through expertise in drug development. From lab to production, cutting-edge technology accelerates processes, optimizes yields, and […]
read more
New Member: Welcome in our cluster to GeneTechX
At GeneTechX, they are developing a nutrigenomics platform that combines genetics and nutritional science to create personalized dietary solutions. Leveraging advanced gene-editing technologies like PrimeCRISPR, they investigate the intricate relationships between genes, diet, and health outcomes. By identifying genetic variations that affect nutrient metabolism, GeneTechX delivers tailored nutrition strategies to enhance health and prevent disease, […]
read more
New Member: Welcome in our cluster to Akribion Therapeutics GmbH
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, […]
read more
New weapons against viruses
Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging […]
read more
BioChatter: making large language models accessible for biomedical research
Introducing an open-source large language model (LLM) framework designed for custom biomedical research Summary Large language models (LLMs) have transformed how many of us work, from supporting content creation and coding to improving search engines. However, the lack of transparency, reproducibility, and customisation of LLMs remains a challenge that restricts their widespread use in biomedical […]
read more
